尼妥珠单抗联合导赤散加减治疗牙龈癌临床评价  

Nimotuzumab Combined with Modified Daochi Powder for the Treatment of Gingival Cancer

作　　者：张鹏[1] 赵军伟[2] 安红丽 ZHANG Peng;ZHAO Junwei;AN Hongli(Operating Room,Tangshan Ninth Hospital,Tangshan,Hebei,China 063000;Department of Stomatology,Tangshan Union Hospital,Tangshan,Hebei,China 063009)

机构地区：[1]河北省唐山市第九医院手术室,河北唐山063000 [2]河北省唐山市协和医院口腔科,河北唐山063009

出　　处：《中国药业》2020年第20期78-80,共3页China Pharmaceuticals

基　　金：河北省卫生和计划生育委员会科研基金[20191626]。

摘　　要：目的探讨尼妥珠单抗联合导赤散加减治疗牙龈癌的临床疗效及对患者生活质量的影响。方法选取唐山市第九医院2016年10月至2017年10月收治的牙龈癌患者88例,按治疗方法的不同分为观察组(45例)和对照组(43例)。两组患者术前术后均予尼妥珠单抗注射液静脉滴注,观察组患者加用导赤散加减治疗,均持续治疗24周。结果观察组总有效率为91.11%,显著高于对照组的76.74%(P<0.05);观察组患者治疗8,16,24周时的白细胞介素6(IL-6)、白细胞介素8(IL-8)、白细胞介素10(IL-10)、肿瘤坏死因子-α(TNF-α)水平,临床症状总分及单项(口腔溃疡、自发性疼痛、牙齿松动、张口困难、颌骨破坏)评分,中医证候总积分及单项(虚火内生、血脉阻滞、牙龈处肿块、口渴便秘、纳呆食少)评分均显著低于对照组,健康调查简表(SF-36)中总体健康及精神健康、生理功能、社会功能评分均显著高于对照组(P<0.05)。结论尼妥珠单抗联合导赤散加减治疗牙龈癌,可降低肿瘤细胞因子水平,明显改善临床症状与中医证候,利于提升患者的生活质量水平。Objective To study the clinical efficacy of nimotuzumab combined with Modified Daochi Powder for the treatment of gingival cancer and its influence on the quality of life.Methods A total of 88 patients with gingival cancer from October 2016 to October2017 in Tangshan Ninth Hospital were retrospectively selected and randomly divided into the observation group(45 cases)and the control group(43 cases)according to different treatment methods.Both groups were given intravenous drip of nimotuzumab injection before and after the operation,and the observation group was treated with Modified Daochi Powder.Both groups were continuously treated for 24 weeks.Results The total effective rate of the observation group was 91.11%,which was significantly higher than76.74%in the control group(P<0.05);the levels of interleukin 6(IL-6),IL-8,and IL-10 in the observation group at 8,16,and24 weeks of treatment,the level of tumor necrosis factor-α(TNF-α),total scores of clinical symptoms and individual scores(oral ulcers,spontaneous pain,loose teeth,difficulty in opening the mouth,jaw destruction scores),total scores of TCM syndromes and individual scores(hyperactivity of fire due to yin deficiency,static blood blocking blood vessels,lump on the gums,thirsty and constipation,anorexia)were significantly lower than those of the control group,and the scores of general health and mental health,physical function,and social function were significantly higher than those of the control group(P<0.05).Conclusion The clinical effect of nimotuzumab combined with Modified Daochi Powder in the treatment of gingival cancer can reduce the level of tumor cytokines,significantly improve clinical symptoms and TCM syndromes,and help improve the quality of life of patients.

关 键 词：尼妥珠单抗 导赤散加减 牙龈癌 口腔肿瘤 肿瘤细胞因子 中西医结合 中医证候 生活质量 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]